PT Mark Dynamics Indonesia Tbk (MARK) Fair Value & Analysis
Healthcare · ID · Market cap 4.1T IDR
Fair value as of: Jul 15, 2026
From 26 valuation models · updated 26 days ago
Share price +0.5% over the past month.
A strong business, screening 20% undervalued on our models.
What matters now
- A fairly wide model range (983.89 IDR to 2,202 IDR) leaves room in how you read the outcome.
- Our model range runs from 983.89 IDR (bear) to 2,202 IDR (bull), base 1,310 IDR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 80/100 (high quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
60‑month range 336.17 IDR – 1,125 IDR · fair‑value band 983.89 IDR – 2,202 IDR · the 1,095 IDR price screens below the 1,310 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.
Analysis
PT Mark Dynamics Indonesia Tbk (MARK) currently trades at 1,095 IDR, while our model-based Fair Value estimate is 1,310 IDR, implying the stock looks roughly 19.6% undervalued today. The Quality Score stands at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, PT Mark Dynamics Indonesia Tbk generated revenue of 885B IDR at a net margin of 33.6%. Revenue grew 23.5% year over year. It earns a return on equity of 31.0%. The balance sheet holds a net cash position of 24.3B IDR. Fundamentals as of Jul 15, 2026
Our scenario range runs from 983.89 IDR (bear case) to 2,202 IDR (bull case); at 1,095 IDR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 116% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 20%, MARK screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (1,724 IDR) versus Asset-Based (158.64 IDR). Highest evidence: Growth DCF (80).
Notify me when MARK reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 77 · Market factors (momentum, volatility) 91
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Mark Dynamics Indonesia Tbk manufactures and sells porcelain former products in Indonesia and internationally. The company offers hand formers for nitrile gloves. Its products used for examination, industrial, medical, household, and custom-made applications. The company was founded in 2002 and is headquartered in Deli Serdang, Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Mark Dynamics Indonesia Tbk reported revenue of 837B IDR in FY2025 versus 1.2T IDR in FY2021, a compound −8.5%/yr. Reported net income was 284B IDR in FY2025, compounding −7.8%/yr from FY2021.
of which total revenue +17.1 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch MARK: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare PT Mark Dynamics Indonesia Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Mark Dynamics Indonesia Tbk (MARK) overvalued or undervalued?
What is the fair value of MARK?
What is the quality score of MARK?
What is the revenue of PT Mark Dynamics Indonesia Tbk (MARK)?
What is the net profit margin of MARK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Mark Dynamics Indonesia Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.